High-resolution proton nuclear magnetic resonance studies of the glucocerebrosidase activator protein from Gaucher spleen.
High-resolution proton nuclear magnetic resonance studies of the glucocerebrosidase activator protein from Gaucher spleen.
复制标题
来自戈谢脾的葡萄糖脑苷脂酶激活蛋白的高分辨率质子核磁共振研究。
DOI:
10.1021/bi00344a052
复制
发表时间:
1985
期刊:
影响因子:
2.9
通讯作者:
Mishra,PK
中科院分区:
文献类型:
--
作者:
Sheh,L;Glew,RH;Bothner-By,AA;Mishra,PK
Department of Chemistry, Carnegie-Mellon University, Pittsburgh, Pennsylvania 15213 Received February 1, 1985 abstract: A heat-stable protein factor (HSF) obtained from the spleen of a patient with Gaucher’s disease that activates glucocerebrosidase was studied by 600-MHz proton NMR spectroscopy. Assignments for a number of aromatic and aliphatic resonances were made on the basis of spin-decoupling, pH-titration, and resolution-enhancement experiments. The upfield ring current shifted aliphatic region and the downfield aromatic region were examined by nuclear Overhauser effect (NOE) methods using both pulsed Fourier-transform spectroscopy and correlation spectroscopy. It was found that a number of upfield-shifted methyl groups and certain methylene groups of specific aliphatic amino acid residues are in proximity relationships with several aromatic residues, forming a compact hydrophobic clustering site. Of special interest, tyrosine A, phenylalanine A, tryptophan Bh and tryptophan B2 were found to be located close to a cluster of aliphatic residues, indicating that the hydrophobic site of the HSF is conformationally rigid and its tertiary structure very compact. A two-dimensional structural model of the hydrophobic site of HSF is proposed.(jTaucher’s disease is an inherited lysosomal storage disease in which glucocerebroside accumulates in mononuclear pha-gocytic cells of the reticuloendothelial systembecause of a marked deficiency of glucocerebrosidase (glucocerebroside:0-glucosidase; EC 3.2. 1.45) activity (Lee, 1968; Fredrickson & Sloan, 1972; Brady & Barranger, 1983). In recentyears, much effort has been devoted to improving our understanding of the regulation of the enzyme and to explaining the molecular basis of the distinction between the clinical extremes of